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ABSTRACT 
INRODUCTION 
Metabolic syndrome and hypothyroid are both individually risk factors for 
coronary heart disease. Relation between them is not established so far 
conclusively. 
AIM OF THE STUDY 
To study the prevalence and to find the types of thyroid dysfunction in 
Metabolic Syndrome and to find the association of Thyroid Dysfunction and 
Metabolic Syndrome. 
MATERIALS AND METHODS 
A total of 60 Patients with metabolic syndrome fulfilling IDF criteria were 
selected the study. Detailed history of medication, and anthropometric 
measurements were noted in a semi-structured proforma. Blood pressure was 
recorded in right upper limb in sitting posture. After eight hours of fasting, blood 
drawn for fasting blood sugar, lipid profile and thyroid assay in a single sitting. 
Then statistical analysis made using SPSS22 and excel. 
 
RESULTS AND OBSERVATIONS 
In this study, thyroid dysfunction prevalence is 18.33% among metabolic 
syndrome patients. Subclinical Hypothyroidism is 15% prevalent in metabolic 
syndrome patients and Overt Hypothyroidism is 3.3% prevalent. There is no 
incidence of either overt or subclinical Hyperthyroidism in our study population. 
The prevalence of thyroid dysfunction and hypothyroidism in metabolic syndrome 
patients are higher than the prevalence in normal population, which is 5.9% for 
thyroid dysfunction and 4.6% for hypothyroidism (0.3% overt and 4.3% sub 
clinical hypothyroidism). Incidence of metabolic syndrome in significantly higher 
in women (25.8) then in men (8%) with metabolic syndrome 
CONCLUSION 
Thyroid dysfunction occurs in 18.33% of metabolic syndrome patients. 
Prevalence of Subclinical hypothyroidism (15.0%) and Overt Hypothyroidism 
(3.33%) in metabolic syndrome patients which is higher than that of general 
population. One sixth of metabolic syndrome patients or every sixth metabolic 
syndrome had Subclinical Hypothyroidism.  Prevalence of thyroid dysfunction is 
much more common in Females with thyroid dysfunction than male. Exclude the 
presence of Thyroid dysfunction while managing metabolic syndrome patients. 
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INTRODUCTION 
  
Each year mortality due to coronary artery disease and 
cerebrovascular disease are on the rise. Though there are multiple risk 
factors leading to these terminal illnesses, few of these risk factors appear in 
groups. Characteristic of this group is presence of central obesity and insulin 
resistance; they also have high blood pressure, high triglyceride levels and 
abnormal fasting blood sugar levels. 
These groups of risk factors are known as Metabolic Syndrome. There 
is high risk of developing cerebrovascular disease and cardiovascular events 
in people who have metabolic syndrome. With the changing lifestyle and 
food habits, there is a raise in incidence of obesity and Metabolic Syndrome. 
 Thyroid disease is associated with atherosclerotic cardiovascular 
disease. This association may be in part be explained by thyroid hormone’s 
regulation of lipid metabolism and its effect on blood pressure. 
Thyroid hormones have ubiquitous effects and influence the function of 
most organs. This hormone appears to serve as a general pacemaker 
accelerating metabolic process and may be associated with metabolic 
syndrome.(9) 
Both Metabolic syndrome and thyroid dysfunction are associated with 
increased risk of atherosclerotic heart disease. Little is known about the 
relationship between metabolic syndrome and thyroid dysfunction. Only a 
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few small studies have been performed.(10,11) In a cross sectional study in 
220 metabolic syndrome patients, it was found that subclinical 
hypothyroidism was prevalent in 16.4% of metabolic syndrome patients.(10) 
In another study, it was found that metabolic syndrome was prevalent in 
thyroid dysfunction patients.(11) There is no information available in 
literature regarding this association in this part of the country. Therefore, the 
association of thyroid dysfunction with metabolic syndrome was evaluated 
in this study. 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of thyroid dysfunction in metabolic 
syndrome. 
2. To find the types of thyroid dysfunction in Metabolic Syndrome. 
3. To find the association of Thyroid Dysfunction and Metabolic 
Syndrome.  
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REVIEW OF LITERATURE 
 
THE METABOLIC SYNDROME 
―The metabolic syndrome is also known as syndrome X, (1) the 
insulin resistance syndrome, (12) and the deadly quartet. (13) The 
constellation of metabolic abnormalities includes insulin resistance, glucose 
intolerance, central obesity, dyslipidemia, and hypertension, as well 
documented risk factors for cardiovascular disease‖. When grouped together, 
they are associated with increased risk of cardio vascular disease. (14, 15) 
The concept of metabolic syndrome exists at least 80 years. (16) That was 
first described in the 1920s by Klein, a Swedish physician, as the clustering 
of hypertension, hyperglycaemia, and gout. 
DEFINING THE METABOLIC SYNDROME 
Although Reaven GM already highlighted the concepts of insulin 
resistance and metabolic syndrome in 1988, it was not until 1998 before the 
first attempt for an internationally accepted definition was put forward. (17) 
Since then several expert groups have formulated and adapted definitions.  
In an attempt to achieve some agreement on definition, and to provide a tool 
for clinicians and researchers, a WHO consultation proposed a set of criteria. 
Subsequently, the National Cholesterol Education Program’s Adult 
Treatment Panel (NCEP: ATP III) and the European Group for the Study of 
Insulin Resistance (EGIR) have formulated definitions. These definitions 
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agree on essential components – glucose intolerance, obesity, hypertension 
and dyslipidaemia – but do differ in the detail and criteria. 
WHO 1999(18)  
―Diabetes or impaired fasting glycaemia or impaired glucose tolerance 
or insulin resistance plus two or more of the following: 
1. Obesity: Body mass index >30 kg/m2 or waist: hip ratio >0.9 in males or 
>0.85 in females. 
2. Dyslipidemia: triglycerides ≥ 1.7 mmol/L or HDL < 0.9(male) or 
<1.0(female) mmol/L. 
3. Hypertension: Blood pressure ≥ 140/90 mm Hg. 
4. Microalbuminuria: albumin excretion ≥ 20 microg/min.‖ 
EGIR 1999(19) 
―Insulin resistance plus two or more of the following: 
1. Central obesity: Waist circumference ≥ 94 cm (male) or ≥ 80 cm (female). 
2. Dyslipidemia: Triglycerides > 2.0 mmol/L or HDL cholesterol <1.0 
mmol/L. 
3. Hypertension: Blood pressure ≥ 140/90 mm Hg and/or medication. 
4. Fasting plasma glucose ≥ 6.1 mmol/L.‖ 
ATP III 2001(20) 
―Three or more of the following: 
1. Central Obesity: Waist circumference >102 cm (male) or >88 cm 
(female). 
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2. Hypertriglyceridemia: Triglycerides ≥ 1.7 mmol/L. 
3. Low HDL cholesterol: <1.0 mmol/L (male) or <1.3 mmol/L (female). 
4. Hypertension: Blood pressure ≥ 135/85 mm Hg or medication. 
5. Fasting plasma glucose ≥ 6.1 mmol/L.‖ 
AHA/NHLBI 2005(21) 
―Any three of the five constitute diagnosis of metabolic syndrome. 
1. Elevated waist circumference ≥ 102 cm (male) or ≥ 88 cm (female). 
2. Elevated TGL ≥ 150 mgs/dl or medication. 
3. Reduced HDL cholesterol < 40 in men or < 50 in women. 
4. Elevated BP ≥ 130/85 mm Hg or medication. 
5. Elevated fasting glucose ≥ 100mgs/dl or medication.‖ 
 
IDF 2005 
―For a person to be defined as having the metabolic syndrome they must 
have: 
1. Central obesity – waist circumference ≥ 94 cm for European men and   
≥ 80 cm for European women. For South Asians – Waist 
circumference ≥ 90 for men and ≥ 80 for women.  
plus any two of the following four factors: 
2. Raised TG level ≥ 150 mgs/dl or any specific treatment. 
3. Reduced HDL cholesterol < 40 mg/dl in males and < 50 mg/dl in 
females. 
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4. Raised blood pressure ≥ 130/85 mm Hg or medication. 
5. Raised fasting glucose ≥ 100 mg/dl or previously diagnosed type 2 
diabetes.‖ 
 
―A major issue for the IDF consensus consultation was the fact that 
criteria used for obesity in Asian and other populations could be different 
from those used in the west. This issue was supported by International 
Obesity Task Force. (24) They noted that in urban Asians, the body mass 
index range of 23-24 has an equivalent risk of type 2 diabetes, hypertension, 
and dyslipidaemia as a body mass index of 25- 29.9 in white people.‖  
PREVALENCE OF THE METABOLIC SYNDROME  
A very consistent finding is that the prevalence of the metabolic 
syndrome is highly age-dependent and differs with different diagnostic 
criteria. ―Females are more prevalent than male all over the world. The 
prevalence increased from 7% in aged 20-29 to 44% for those aged 60-69 
years. (25) The prevalence of metabolic syndrome in Chennai was 11.2% 
and 41.1% using EGIR and ATP III criteria respectively (26, 27).‖ 
Over the past two decades, a striking increase in the number of people 
with the metabolic syndrome worldwide has taken place. This increase is 
associated with the global epidemic of obesity and diabetes; with the 
elevated risk not only of diabetes but also of cardiovascular disease from the 
metabolic syndrome.  
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PATHOPHYSIOLOGY 
―The most accepted underlying hypothesis to describe the 
pathophysiology of the metabolic syndrome is insulin resistance. A major 
contributor to the development of insulin resistance is an overabundance of 
circulating fatty acids. (28) Insulin is important to both antilipolysis and the 
stimulation of lipoprotein lipase.‖ Of note, the most sensitive pathway of 
insulin action is the inhibition of lipolysis in adipose tissue. Thus, when the 
insulin resistance develops, the increased amount of lipolysis of stored 
triacylglycerol molecules in adipose tissue produces more fatty acids, which 
could further inhibit antilipolytic effect of insulin, creating additional 
lipolysis. Upon reaching insulin sensitive tissues, excessive fatty acids create 
insulin resistance by the added substrate availability and by modifying 
downstream signalling. ―Presumably, these biochemical changes in insulin 
mediated signalling pathways result in decrease in insulin-mediated glucose 
transport and metabolism in the metabolic syndrome as well.‖ 
OBESITY AND INCREASED WAIST CIRCUMFERENCE  
For several definitions of the metabolic syndrome waist circumference 
is included. With increase in intra-abdominal or visceral adipose tissue, a 
higher rate of adipose tissue-derived free fatty acids go to the liver through 
the splanchnic circulation. Whereas increase in abdominal subcutaneous fat 
would release lipolysis product into the systemic circulation and avoid direct  
12 
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effects on hepatic metabolism. Yet, perhaps by a mechanism related to free 
fatty acid flux and metabolism, the relative predominance of visceral rather 
than subcutaneous adipose tissue with increased waist circumference in    
Asians and Asian Indians renders the relative prevalence of the syndrome 
higher than African-American men in whom subcutaneous fat predominates.  
DYSLIPIDAEMIA  
In general, with increase in free fatty acid flux to the liver, increased 
production of Apo-B containing triglyceride rich very low density 
lipoproteins occur. In the setting of insulin resistance, increased flux of free 
fatty acids to the liver increases hepatic triglycerides synthesis; however, 
under physiologic conditions, insulin inhibits rather than increase the 
secretion of very low density lipoproteins into the systemic circulation. 
Hypertrygleridemia is an excellent reflection of the insulin resistant 
condition and one of the important criteria for diagnosis of the metabolic 
syndrome. The other major lipoprotein disturbance in the metabolic 
syndrome is a reduction in HDL cholesterol. This reduction is a consequence 
of changes in HDL composition and metabolism. In the presence of 
hypertriglyceridaemia, a decrease in the cholesterol content of HDL results 
from decreases in the cholesterol ester content of the lipoprotein core with 
variable increases in triglyceride making the particle small and dense, a 
function in part of cholesterol ester transfer protein. 
14 
 
This leads to increased clearance of HDL from the circulation. In 
addition to the clearance of HDL composition of LDL is also modified 
which is attributable to relative depletion of unesterified cholesterol, 
esterified cholesterol, and phospholipids with either no change or an increase 
in LDL triglyceride. ―Small dense LDL might be more atherogenic than 
buoyant LDL because (1) it is more toxic to the endothelium; (2) it is more 
able to transit through the endothelial basement membrane; (3) it adheres 
well to glycosaminoglycans; (4) it has increased susceptibility to oxidation; 
and/or (5) it is more selectively bound to scavenger receptors on monocyte  
derived macrophages.‖ 
GLUCOSE INTOLERANCE 
The defects in insulin action on glucose metabolism include 
deficiencies in the ability of the hormone to suppress glucose production by 
the liver and kidney, and to mediate glucose uptake and metabolism in 
insulin sensitive tissues (i.e., muscle and adipose tissue). Insulin resistance in 
pancreatic islet-beta cells implies that signals that generate glucose 
dependent insulin secretion have been adversely modified, and fatty acids 
are prime candidates. Although free fatty acids can stimulate insulin 
secretion, increasing and prolonged exposure to excessive concentrations 
results in fall in insulin secretion.  
The mechanism for this alteration has been attributed to lipotoxicity 
through several potential different mechanisms. In people with genetic 
15 
 
predispositions to development of diabetes, the presumed stress of the 
insulin resistant environment on beta cell function causes glucose intolerance 
and ultimately higher risk of diabetes  
HYPERTENSION  
The relation between insulin resistance and hypertension is well 
established, and relates to several different mechanisms.  
First, it is important to note that insulin is a vasodilator when given 
intravenously to people of normal weight, with secondary effects on sodium 
reabsorption in the kidney.  
Evidence indicates that sodium reabsorption is increased in white 
people but not Africans or Asians with the metabolic syndrome. In the 
setting of insulin resistance, the vasodilatory effect of insulin can be lost, but 
the renal effect on sodium reabsorption preserved. Fatty acids themselves 
can mediate relative vasoconstriction. Insulin also increases the activity of 
the sympathetic nervous system, an effect that might also be preserved in the 
setting of the insulin resistance.  
PROINFLAMMATORY CYTOKINES  
The association of the metabolic syndrome with inflammation is well 
documented. The increases in proinflammatory cytokines including 
interleukin 6, resistin, and tumor necrosis factor (TNF) and C – reactive 
protein reflect overproduction by the expanded adipose tissue mass. 
Evidence suggests that monocyte-derived macrophages reside in adipose 
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tissue and might be at least in part the source of the generation of 
proinflammatory cytokines locally and in the systemic circulation. There is 
increasing evidence that insulin resistance in the liver, muscle, and adipose 
tissue is not only associated with the abundance of proinflammatory 
cytokines (and relative deficiency of the anti-inflammatory cytokine 
adiponectin), but is a direct result of this burden.  
ADIPONECTIN  
Adiponectin is an anti-inflammatory cytokine that is produced 
exclusively by adipocytes. Adiponectin both enhances insulin sensitivity and 
inhibits many steps in the inflammatory process. In the liver, it inhibits both 
the expression of hepatic gluconeogenic enzymes and the rate of endogenous 
glucose production. In muscle, it increases glucose transport and enhances 
fatty acid oxidation, effects that are partly due to the activation of AMP 
kinase.  
In mice decreased circulating concentrations of Adiponectin could be 
important in producing changes in metabolism consistent with the metabolic 
syndrome.  
CHANGES ASSOCIATED WITH INSULIN RESISTANCE 
“LIPOPROTEINS 
 Increased apo B 
 Decreased apo A-1 
 Increased small dense LDL 
17 
 
 Decreased HDL 
 Increased Apo C-III 
 PROTHOMBOTIC 
 Increased Fibrinogen 
 Increased plasminogen activator inhibitor 1 (PAI - 1) 
 Increase viscosity 
INFLAMMATORY MARKERS 
 Increased white blood cell count 
 Increased Interleukin 6 
 Increased tumor necrosis factor alpha 
 Increased resistin 
 Increased C-reactive protein 
 Decreased adiponectin 
VASCULAR 
 Microalbuminuria 
 Increased asymmetric dimethyl arginine 
OTHER 
 Increased uric acid 
 Increased homocysteine 
 Non-alcoholic steatohepatitis (NASH) 
 Polycystic ovaries syndrome (PCOS) 
 Obstructive sleep apnea (OSA).‖ 
18 
 
MANAGEMENT OF THE METABOLIC SYNDROME 
The primary goal of management of the metabolic syndrome is to reduce the 
risk for clinical atherosclerotic disease. A closely related goal is to decrease 
the risk for type 2 diabetes in those patients who do not yet manifest clinical 
diabetes. The first line therapy is to reduce the major risk factors: stop 
cigarette smoking and reduce LDL-C, blood pressure and glucose levels to 
recommended goals. Lifestyle modifications are the first line interventions to 
reduce the metabolic risk factors. The major lifestyle interventions include 
weight loss, increased physical activity and modification of diet. For 
individuals at higher risk consideration must be given to specific therapies 
for the metabolic risk factors. (21) Selective CB1- receptor blockade drugs 
like Rimonabant significantly reduces the several metabolic risk factors in 
metabolic syndrome. (29,30) 
THERAPEUTIC GOALS AND RECOMMENDATIONS 
Abdominal obesity: 
Goal: 10% weight loss first year, thereafter continued weight loss or 
maintain weight.  
Recommendation: caloric restriction; regular exercise; behaviour 
modification 
Physical inactivity: 
Goal: regular moderate-intensity physical activity.  
Recommendation: 30–60 min moderate-intensity exercise daily  
19 
 
Atherogenic diet: 
Goals: reduced intakes of saturated fats, Trans-fats and cholesterol. 
Recommendations: saturated fat 7% of total calories; reduce trans-fat; 
Dietary cholesterol < 200 mg daily; total fat 25–35% of total calories. 
Cigarette smoking:  
Goal and recommendation: complete smoking cessation 
LDL-Cholesterol: 
  “High risk patients are those who have established cardiovascular 
disease, diabetes, or 10 year risk for coronary heart disease more than 20%. 
Moderately high risk patients are those with ten year risk of coronary artery 
disease between 10-20%.‖ 
 ―The cholesterol guideline defined four statin benefit groups 
1. all individuals who have clinical atherosclerotic cardiovascular disease 
(ASCVD), therefore considered ―secondary prevention 
2. those with LDL cholesterol ≥190 mg/dL without a secondary cause such 
as a high intake of saturated or trans fats, various drugs, or certain 
diseases; 
3. individuals with diabetes without established cardiovascular disease who 
are 40–75 years old and have LDL cholesterol of 70–189 mg/dL; 
4. those without established ASCVD without diabetes who are 40–75 years 
old and who have LDL cholesterol of 70–189 mg/dL and a calculated 
ASCVD risk ≥7.5%.‖ 
20 
 
Goals:  
LDL cholesterol < 100 mg/dl (2·6 mmol/L). 
―Recommendations:  
I. High-risk patients—lifestyle therapies and LDL cholesterol lowering 
drugs to achieve recommended goal. Moderately high-risk patients—
lifestyle therapies; add LDL-cholesterol lowering drug if necessary to 
achieve recommended goal when baseline LDL cholesterol < 130 
mg/dl (3·4 mmol/L).  
II. Moderate risk patients (those with 10-year risk of coronary heart 
disease less than 10%) —lifestyle therapies; add LDL-cholesterol 
lowering drug if necessary to achieve recommended goal when 
baseline LDL cholesterol _1·6 g/L (4·1 mmol/L).‖ 
High triglyceride:  
Goal: insufficient data to establish goal  
HDL-Cholesterol: 
Recommendation: High-risk patients—consider adding fibrate (Preferably 
fenofibrate) or nicotinic acid to LDL-lowering drug therapy  
Elevated blood pressure: 
Goals:  
Blood pressure < 135/85 mm Hg.  
21 
 
 For diabetes or chronic kidney disease:  Blood pressure < 130/80 mm Hg.  
Recommendation: lifestyle therapies; add antihypertensive drug(s) when 
necessary to achieve goals of therapy.  
Elevated glucose:  
Goal: maintenance or reduction in fasting glucose if _1 g/L (5·5 mmol/L). 
HbA1C < 7.0% for diabetes.  
Recommendation:  
Lifestyle therapies; add hypoglycaemic agents as necessary to achieve goal 
Fasting glucose or HbA1C.  
Prothrombotic state:  
Goal: reduction of prothrombotic state.   
Recommendation:   
High-risk patients—initiate low-dose aspirin therapy; consider clopidogrel if 
aspirin is contraindicated. Moderately high-risk patients—consider low-dose 
aspirin therapy. Proinflammatory state Recommendations: no specific 
therapies 
 
THYROID DYSFUNCTION  
The thyroid is one of the largest endocrine glands in the body. Thyroid 
produces three types of hormones, namely thyroxin (T4), triiodothyronine 
(T3) and calcitonin. Among them T3 and T4 are two closely related 
hormones. Together they play a major role in cell differentiation during 
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development, and maintain metabolic and homeostasis in adults. Up to 40% 
of the T4 is converted to T3 by peripheral organs such as the liver, kidney 
and spleen.  
PHYSIOLOGY OF THYROID HORMONES  
       Thyroid hormone is produced from thyroglobulin (Tg), a large 
glycoprotein. Inside thyroid follicle thyroglobulin is iodinated on the 
tyrosine residues. They are coupled via ether linkage. The iodinated 
thyroglobulin molecules are reuptaked by thyroid follicular cells where they 
undergo proteolysis and release the newly formed thyroid hormones  T3 and 
T4. 
 The first major step in thyroid synthesis is iodine uptake  from the 
gut.  iodine absorbed in the gut is converted into iodide and is  transported in 
the blood bound to albumin. It is then actively transferred into the thyroid 
follicular cells by "Iodide trapping" by sodium iodide symporter. The 
trapped iodide is oxidized to iodine and combines with tyrosine to form 
Mono iodotyrosine (MIT) and Diiodotyrosine (DIT) . MIT and DIT are 
coupled to form T3 whereas two DIT couple to form T4. Oxidation, 
Iodination and coupling reactions are catalyzed by "Thyroid Peroxidase". 
Thyroid hormones thus produced are bound with thyroglobulin until 
secreted. Once secreted, it is transported in two forms in the blood. One is 
bound form in which T3 and T4 are bound to plasma proteins namely 
thyroid binding globulin, pre albumin and albumin. T4 is predominantly 
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bound to thyroid binding globulin whereas T3 is predominantly bound to 
albumin. The other form is free T3 and T4. These free forms are in 
equilibrium with bound form.  
In the periphery one third of T4 is converted to T3 by 5' Deiodinase 
and 45% to rT3 by 5 Deiodinase. They are further metabolized to 
Diiodothyronine. Only about 13% of T3 is produced from thyroid gland and 
remaining 87% is formed from T4.  
The production of thyroxin is regulated by thyroid-stimulating 
hormone (TSH), released by anterior pituitary. The thyroid hormones and 
thyrotropes form a negative feedback loop: TSH production is suppressed 
when T4 levels are high, and vice versa. The TSH production itself is 
modulated by thyrotropin-releasing hormone, which is produced by the 
hypothalamus. The TSH is extremely sensitive to the levels of thyroid  
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FIGURE 2: REGULATION OF THYROIS HORMONE SYNTHESIS 
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hormones in circulation and can be used as a useful tool in detection of 
thyroid abnormalities rather than using T4 or T3 levels.  
The thyroid dysfunction is simply classified as hypothyroidism, 
hyperthyroidism, sub clinical hypothyroidism and sub clinical 
hyperthyroidism depending upon the TSH and thyroid hormone levels. 
Clinical status    TSH level  Thyroid hormone  
Hypothyroid    High   Low 
Hyperthyroid    Low   High 
Sub clinical Hypothyroid  High   Normal 
Sub clinical Hyperthyroid Low  Normal 
HYPOTHYROIDISM 
Hypothyroidism is the condition resulting from lack of the effects of 
the thyroid hormone on body tissues. Hypothyroidism is a common 
condition. (31, 32) The overall incidence in the population is approximately 
1% to 2 % (33, 34). The serum TSH levels more than 10mU/L and 
associated with low values of thyroid hormones. Florid hypothyroidism can 
be diagnosed clinically.  
―The symptoms of hypothyroidism in descending order of frequency are: 
 Tiredness, Weakness 
 Dry Skin 
 Feeling Cold 
 Hair Loss 
26 
 
 Difficulty In Concentrating And Poor Memory 
 Constipation 
 Weight Gain With Poor Appetite 
 Dyspnea 
 Hoarse Voice 
 Menorrhagia (Later Amenorrhea) 
 Paraesthesia 
 Impaired Hearing 
The signs of hypothyroidism in descending order of frequency are as 
follows:  
 Tiredness, weakness 
 Dry coarse skin 
 Cool peripheral extremities 
 Puffy face, hands and feet (myxoedema) 
 Diffuse alopecia 
 Bradycardia 
 Peripheral oedema 
 Delayed tendon reflex relaxation 
 Carpal tunnel syndrome 
 Serous cavity effusions.‖ 
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HYPERTHYROIDISM 
Hyperthyroidism is the condition resulting from the effect of excessive 
amounts of thyroid hormones in the body tissues. Thyrotoxicosis is a 
synonym. Grave’s disease is the most common cause of hyperthyroidism. 
Approximately 0.5% to 1% of the population suffers from hyperthyroidism. 
The TSH levels are suppressed, usually <0.1 mU/L and associated with high 
levels of thyroid hormones. 
 ―The symptoms of hyperthyroidism in descending order of frequency are as 
follows: 
 Hyperactivity, irritability, dysphoria. 
 Heat intolerance and sweating 
 Palpitations 
 Fatigue and weakness 
 Weight loss with increased appetite 
 Diarrhoea 
 Polyuria 
 Oligomenorrhea, loss of libido 
The signs of hyperthyroidism in descending order of frequency are follows: 
Tachycardia; Atrial fibrillation in the elderly 
 Tremors 
 Goiter 
 Warm, moist skin 
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 Muscle weakness, proximal myopathy 
 Lid retraction or lid lag 
 Gynaecomastia.‖ 
SUB CLINICAL HYPOTHYROIDISM 
According to the latest consensus statement by the American Association of 
Clinical Endocrinologists, the American Thyroid Association and The 
Endocrine Society, sub clinical hypothyroidism is defined as an elevated 
serum TSH level (4.5mU/L to10mU/L) associated with normal total or free 
T4 and T3 levels. (35) Several alternative names have been proposed to 
describe this condition and include compensated hypothyroidism, mild 
thyroid failure, and mild hypothyroidism. The overall prevalence is 2% to 
8% in the general population. (33, 34, 36)  
SUB CLINICAL HYPERTHYROIDISM  
Sub clinical hyperthyroidism is defined as low serum TSH levels (0.1mU/l 
to 0.4mU/L) associated with normal free T4 and free T3 levels. Sub clinical 
hyperthyroidism is much less common than sub clinical hypothyroidism. 
The prevalence is about 2%; it is more common in women, blacks, and the 
elderly.  
NON THYROIDAL ILLNESS  
Alteration in serum thyroid hormones occurs in wide variety of illness which 
predominantly affects the T3 level and no intrinsic disease of thyroid gland 
is detected. It is variously termed as Low T3 syndrome, Sick euthyroid 
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syndrome, Non thyroidal illness syndrome and Thyroid hormone adaptation 
syndrome. This syndrome occurs in wide variety of illness as follows: 
a) Acute critical illness and febrile illness such as infections, 
b) Myocardial infarction etc. 
c) Injuries such as burns, trauma, etc. 
d) Surgery 
e) Fasting 
f) Diabetes mellitus 
g) Liver disease 
h) Renal disease 
i) Ketogenic diet 
j) Drugs such as glucocorticoids, dopamine, phenytoin and beta 
k) blockers 
l) Malignancy 
m) Psychiatric illness 
In non-thyroidal illness state, initially there is decrease in serum T3 level, 
both total and free T3 (FT3). This is associated with increase in reverse T3 
(rT3). 
As illness progresses, there is decrease in serum T4 also, a state called 
"Low T3, T4 syndrome". Although total T4 level decreases, the free T4 
(FT4) remains normal or slightly reduced. In spite of this reduced T3 and T4 
level, serum TSH level remains normal or reduced, by which it is 
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differentiated from primary hypothyroidism. But many studies have showed 
slight elevation of TSH level in Non thyroidal illness in the absence of 
hypothyroidism. 
 
THYROID FUNCTION AND THE METABOLIC SYNDROME 
It is well documented that hypothyroidism is associated with all the 
parameters of metabolic syndrome, (32) except increase in fasting blood 
glucose.  
 
OBESITY 
The obesity (increase in waist circumference) is the important symptom and 
sign of hypothyroidism. More than 60% of hypothyroid patients have obesity 
(increase in waist circumference). (37) There is decrease in basal metabolic 
rate and energy metabolism in hypothyroidism. 
 
 HYPERTENSION  
In hypothyroidism, the hemodynamic alterations cause narrowing of pulse 
pressure, prolongation of circulation time and decrease in blood flow to the 
tissues. (38) Systemic vascular resistance is increased in hypothyroidism and 
results in hypertension. (39) Rotterdam study(6) suggested that there was a 
twofold increase in risk of atherosclerosis in hypothyroid patients. 
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LIPID PROFILE  
Both the synthesis and degradation of lipid are depressed in hypothyroidism, 
the latter especially so, the net effect being one of the lipid accumulation, 
especially of low-density lipoprotein cholesterol and triglycerides. (40) The 
increase in serum cholesterol in hypothyroidism is accompanied by 
increased levels of serum phospholipids, serum triglycerides, and the low 
density lipoprotein cholesterol. The activity of cholesterol ester transfer 
protein is decreased in hypothyroidism, thus high density lipoprotein 
cholesterol level reduced in hypothyroidism. (41)  
PREVIOUS RELATED STUDIES  
Thyroid function is associated with components of the metabolic 
syndrome in euthyroid subjects. (42) In this population based study there 
was a negative correlation between thyroid hormone levels (free T4 and free 
T3) and metabolic syndrome components, Apo B and insulin resistance 
levels in people with euthyroid state. Free T4 was very significantly related 
to four of five metabolic syndrome components - waist circumference, 
fasting glucose, high density cholesterol and triglycerides and insulin 
resistance level, which assessed by the homeostasis model assessment 
(HOMA) model. i.e. low normal free T4 was associated with higher 
triglycerides, lower high density lipoprotein cholesterol, increased fasting 
glucose and higher waist circumference. Free T3 levels correlated well with 
systolic blood pressure, triglycerides and Apo-B levels. In insulin resistance 
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individuals are more susceptible to the association of TSH with higher low 
density lipoprotein cholesterol and lower high density lipoprotein 
cholesterol. (43) The morbid obese subjects have higher level of T3, T4 and 
TSH, probably of the reset of their central thyrostat at higher levels. (44) In a 
study done by Uzunulu et al., at Japan they have analyzed the prevalence of 
sub clinical hypothyroidism among 220 metabolic syndrome patients. They 
found that sub clinical hypothyroidism was 16.4% prevalent in metabolic 
syndrome patients. (10) One sixth of metabolic syndrome patients had sub 
clinical hypothyroidism and more prevalent in female gender.  
In a study from Nepal, done by Chandra L et al., found that the 
metabolic syndrome prevalent in 21.1% of thyroid dysfunction patients. (11) 
They have assessed the association of metabolic syndrome and its 
components with thyroid dysfunction in 100 female patients. This study 
found that the prevalence of overall metabolic syndrome was 32%, more in 
euthyroid group (21/48) than hyperthyroid group (5/24) and hypothyroid 
group (6/28)  
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METHODS AND MATERIALS 
Study group :  Patients with metabolic syndrome attending 
Medical, diabetic and hypertensive opd. 
Study design  :  Single Center Non-randomized cross-sectional study 
Place Of Study   :    Govt. Kilpauk Medical College and Hospital 
Duration of study  :    6 months 
Conflict of interest  :     Nil 
Hazards of study    :     Nil   
 
SETTING: 
The study was conducted on the out patients attending the Institute of 
Internal Medicine, Department of Diabetology and Hypertension OPD in 
Kilpauk Medical College and l Hospital, Chennai.        
 
METHODOLOGY 
Detailed history of medication, and anthropometric measurements like 
height, weight, waist circumference were noted in a semi-structured 
proforma. Blood pressure was recorded in right upper limb in sitting posture. 
After eight hours of fasting, blood drawn for fasting blood sugar, lipid 
profile and thyroid assay in a single sitting. 
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SELECTION OF STUDY SUBJECTS 
 
The patients who fulfilled the criteria for metabolic syndrome by IDF were 
taken into the study. 
―For a person to be defined as having the metabolic syndrome they must 
have: 
 
1. Central obesity – waist circumference ≥ 90 cm for men and ≥ 
80 cm for women.  
 
Plus any two of the following four factors:  
 
2. Raised TG level ≥ 150 mgs/dl or any specific treatment.  
 
3. Reduced HDL cholesterol < 40 mg/dl in males and < 50 mg/dl 
in females.  
 
4. Raised blood pressure ≥ 130/85 mm Hg or medication.  
 
5. Raised fasting glucose ≥ 100 mg/dl or previously diagnosed 
type 2 diabetes‖ 
 
INCLUSION CRITERIA 
 
The patients who fulfilled the criteria of metabolic syndrome as defined by 
IDF 2005 were taken up for this study. 
 
EXCLUSION CRITERIA 
1. Known Hypothyroid / Sub clinical Hypothyroid 
2. Patients with chronic illness.  
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3. Taking Steroids  
4. Severely ill patients  
5. Pregnant Women  
6. Individuals below 18 Yrs.  
 
CONSENT 
Informed consent will be obtained from all participants.  
 
DATA COLLECTION 
The data of each patient will be collected on a proforma specially designed 
for this study and which includes demographic details, past medical history, 
clinical data and biochemical results will be analysed for statistical 
significance and correlation. 
 
SAMPLE SIZE 
As per formula, sample size was calculated to be 60. 
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DEFINITIONS 
Euthyroidism is defined as 
TSH – 0.4 mU/L to 4.5mU/L 
FT4 – 0.70 ng/dl to 1.80 ng/dl 
Sub-clinical hypothyroidism 
TSH – 4.51 mU/L to 10.0 mU/L 
FT4 – 0.70 ng/dl to 1.80 ng/dl 
Hypothyroidism 
TSH – > 10.0 mU/L 
FT4 – < 0.70 ng/dl 
Sub-clinical Hyperthyroidism 
TSH – 0.1 mU/L to 0.4 mU/L 
FT4 – 0.70 ng/dl to 1.80 ng/dl 
Hyperthyroidism 
TSH – < 0.1 mU/L 
FT4 – > 1.80 ng/dl 
STATISTICAL ANALYSIS 
SPSS 12 and Excel were used for data analysis 
LIMITATIONS 
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Small no of study subjects. 
FT3 levels not assessed. 
CONFLICT OF INTEREST 
None 
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Results and 
Observations  
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Results and Observations. 
 
POPULATION CHARACTERISTICS 
Total of 60 patients included in the study based on the inclusion and 
exclusion criteria of metabolic syndrome. Among them 33 were women and 
27 were men. Women constitute around 55%of total cases and rest 45% by 
men. 
Age of the women ranges from 33 to 62 years with mean age 45.1 and 
Standard Deviation 7.6. Age of the men ranges from minimum of 30 to 
maximum of 67 with mean of 46.5 and Standard deviation of 9.7.  
According to age, 7 patients were less than 35 years old. 24 patients 
were in the age 35-45 age group, 19 were in 45-55 age group and 10 patients 
were above 55 years. Population characteristics were shown in the Table 1. 
 
Table 1: Descriptive statistics: SEX-MALE 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 25 30 67 46.59 9.775 
Valid N 
(listwise) 
25         
a. SEX  = Male 
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Table 2: Descriptive statistics: SEX-FEMALE 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 35 33 62 45.18 7.609 
Valid N 
(listwise) 
35         
a. SEX  = Female 
 
Table 3: Population Characteristics 
 
AGE GROUP TOTAL NO PERCENTAGE 
CUMULATIVE 
PERCENTAGE 
Male Female 
Up to 35 yrs. 7 11.7% 11.7% 3 4 
36 - 45 yrs. 24 40.0% 51.7% 8 16 
46 - 55 yrs. 19 31.7% 83.3% 8 11 
Above 55 yrs. 10 16.7% 100.0% 6 4 
Total 60 100.0% 100.0% 25 35 
 
 
 
42 
 
Table 4 Frequency table: SEX in study population 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Male 25 41.67 41.67 41.7 
Female 35 58.33 58.33 100.0 
Total 60 100.00 100.00 
 
 
 As we can see most of patients fall in the middle age group from 36 to 
55 years, consistent with the changing lifestyle patterns and raising obesity 
in the middle age group. 
Among the sixty study subjects, twenty eight members (47%) fulfilled 
three parameters for metabolic syndrome, twenty members (33%) fulfilled 
four parameters and twelve members (20%) fulfilled all criteria for 
metabolic syndrome. 
 
Table 5: Frequency table: No of criteria positive for MS in subjects 
Criteria for metabolic 
syndrome  
Frequency Percent 
Cumulative 
Percent 
3 parameters 28 46.7 46.7 
4 parameters 20 33.3 80.0 
5 parameters 12 20.0 100.0 
Total 60 100.0   
 
43 
 
Table 6: Descriptive statistics of the variables in study population 
Descriptive Statistics 
 
N Minimum Maximum Mean 
Standard 
Deviation 
AGE 60 30 67 45.82 8.603 
HEIGHT 60 142 180 157.70 8.945 
WEIGHT 60 69 106 85.20 8.117 
BMI 60 23.96 32.72 26.9952 1.80825 
WC 60 85 116 98.08 7.038 
SBP 60 100 172 140.10 15.685 
DBP 60 66 110 87.23 10.192 
FBS 60 96 200 135.85 23.726 
TC 60 134 291 194.02 33.090 
HDL 60 31 56 44.53 6.342 
TG 60 77 307 169.88 52.497 
FT4 60 0.17 2.27 1.07 0.265 
TSH 60 0.56 154 5.40 19.809 
Valid N 
(listwise) 60 
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 As waist circumference is absolute criteria to define metabolic 
syndrome, it is present in all subjects. The following tables show frequency 
distribution of the other criteria of metabolic syndrome. 
Table 7: Frequency table- Diabetes in study subjects 
  Frequency Percent Cumulative Percent 
Absent 2 3.3 3.3 
Present 58 96.7 100.0 
Total 60 100.0   
 
Table 8: Frequency table- Hypertension in study subjects 
  Frequency Percent Cumulative Percent 
Absent 15 25.0 25.0 
Present 45 75.0 100.0 
Total 60 100.0   
 
Table 9: Frequency table- Triglycerides in study subjects 
  Frequency Percent Cumulative Percent 
Absent 24 40.0 40.0 
Present 36 60.0 100.0 
Total 60 100.0   
 
Table 10: Frequency table- HDL in study subjects 
  Frequency Percent Cumulative Percent 
Absent 35 58.3 58.3 
Present 25 41.7 100.0 
Total 60 100.0   
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THYROID FUNCTION TEST RESULTS 
The TSH in this study was ranging from 0.56mU/L to 154 mU/L and 
free T4 levels ranging from 0.17ng/dl to 2.21ng/dl. Patients were grouped 
into four groups according to the definitions based on TSH and FT4 levels 
and further statistical analysis was done based on these groups. According to 
our definitions, 49 patients found to be euthyroid and two patients were 
hypothyroid. Nine patients had sub clinical hypothyroidism. There were no 
overt hyperthyroid or sub-clinical hyperthyroidism patients in our study. 
 
Table 11: Distribution thyroid parameters 
  N Minimum Maximum Mean 
Standard 
Deviation 
FT4 60 0.17 2.27 1.07 0.265 
TSH 60 0.56 154 5.4 19.809 
Valid N 
(listwise) 
60         
 
 
The TSH in this study was ranging from 0.56mU/L to 154 mU/L and 
free T4 levels ranging from 0.17ng/dl to 2.21ng/dl. Patients were grouped 
into four groups according to the definitions based on TSH and FT4 levels 
  
46 
 
Table 12 : Thyroid status of the study population 
 
 
GROUP NO % MALE FEMALE 
     
EUTHYROID 49 83.33% 23 26 
     
HYPOTHYROID 2 3.33% 1 1 
     
SUB CLINICAL HYPOT 9 15.00% 1 8 
     
SUBCLINICAL HYPERT 0 0% 0 0 
     
HYPERTHYRODISM 0 0% 0 0 
     
 
 
 
 
 
and further statistical analysis was done based on these groups. According to 
our definitions, 49 patients found to be euthyroid and two patients were 
hypothyroid. Nine patients had sub clinical hypothyroidism. There were no 
overt hyperthyroid or sub-clinical hyperthyroidism patients in our study. 
 
According to the age, among patients age less than 35, there were 
seven subjects. Six were Euthyroid and one is Overt hypothyroid. No 
subclinical hypo or hyperthyroid in this group. 
In the age group 36-45 there were 24 subjects, among them eighteen 
were Euthyroid and remaining six were Subclinical hypothyroid. There 
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were no overt hypo or hyperthyroid in this group 
 
Table - 13. Age Wise Thyroid Dysfunction 
 
AGE 
TOTAL 
NO 
EUTHYROID HYPOTHYROID 
SUBCLINICAL 
HYPOTHYROID 
SUBCLINICAL 
HYPERTHYROID 
<35 7 6 1 0 0 
36-45 24 18 0 6 0 
46-55 19 16 1 2 0 
>55 10 9 0 1 0 
 
 
 
 In the age group 46-55, there were 19 members. Among them sixteen 
were Euthyroid; one is overt hypothyroid and other two were Subclinical 
hypothyroid. There was no subclinical hyperthyroid in this group. 
 In the subjects more than 55 years, there were ten members. Among 
them nine were Euthyroid and remaining one is Subclinical Hypothyroid. 
There were no overt hypothyroid or subclinical hyperthyroid in this group. 
 
Based on the metabolic syndrome criteria, of those twenty eight 
patients who fulfilled three of the five risk factors three had thyroid 
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dysfunction (2-hypothyroid and 1-subclinical hyperthyroid); of the twenty 
patients who had four risk factors three had thyroid dysfunction (all 
subclinical hypothyroid); of the twelve patients who had all five risk factors 
five had thyroid dysfunction (one overt hypothyroid and four subclinical 
hypo thyroid). 
 
Table 14: Metabolic Syndrome Parameters Wise Thyroid Dysfunction 
MS 
CRITERIA 
FULFILLED 
TOTAL 
NO 
EUTHYROID HYPOTHYROID 
SUBCLINICAL 
HYPOTHYROID 
SUBCLINICAL 
HYPERTHYROID 
3 28 25 1 2 0 
4 20 17 0 3 0 
5 12 7 1 4 0 
TOTAL 60 49 2 9 0 
 
 
(P valve = 0.36 not significant) 
 
  Presence of thyroid dysfunction based on number of criteria present is 
statistically significant in our study possibly due to limited number of study 
subjects.  
 
 
 
 First thyroid status is analysed with respect to distribution among sex. 
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Table 15: Crosstab Thyroid Status With Respect Sex Distribution 
 
 
Thyroid status 
SEX 
Total 
Male Female 
Euthyroid 
Count 23 26 49 
% within 
SEX 
92.0% 74.3% 81.7% 
Subclinical 
Hypothyroid 
Count 1 8 9 
% within 
SEX 
4.0% 22.9% 15.0% 
Hypothyroid 
Count 1 1 2 
% within 
SEX 
4.0% 2.9% 3.3% 
Total 
Count 25 35 60 
% within 
SEX 
100.0% 100.0% 100.0% 
 
 
 Women has higher incidence of thyroid dysfunction when compared 
to men with metabolic syndrome.  
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Table 16: Chi-Square Tests – thyroid status vs sex 
 
Chi-Square Tests 
  Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 4.914
a
 2 .086 
Likelihood Ratio 5.617 2 .060 
Linear-by-Linear 
Association 
2.275 1 .131 
N of Valid Cases 60     
a. 4 cells (66.7%) have expected count less than 5. The minimum expected 
count is .90. 
 
 
Chi-square tests did not any significance of thyroid status distribution 
with respect to sex in study subjects possibly due to limited number of study 
subjects. 
Analysis of study subjects with respect to number of criteria fulfilled 
for Metabolic syndrome against sex distribution is as follows. 
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Table 17: Distribution Number of MS parameter with respect to sex 
 
MS parameter 
SEX 
Total 
Male Female 
3 
Count 12 16 28 
% within 
SEX 
48.00% 45.71% 46.70% 
4 
Count 7 13 20 
% within 
SEX 
28.00% 37.14% 33.30% 
5 
Count 6 6 12 
% within 
SEX 
24.00% 17.14% 20.00% 
Total 
Count 25 35 60 
% within 
SEX 
100.00% 100.00% 100.00% 
 
Table 18: Chi-Square test – MS parameter vs Sex 
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square .346
a
 2 .841 
Likelihood Ratio .347 2 .841 
Linear-by-Linear 
Association 
.004 1 .947 
N of Valid Cases 60     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected 
count is 5.40. 
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Distribution of  MS parameter with respect to sex in not significant in 
our study. 
Analysis of thyroid status of the study subjects against number of 
criteria fulfilled for Metabolic Syndrome by the subjects.  
Table 19: Distribution- Thyroid status with respect to no. of MS 
parameter 
 
Thyroid status 
MS parameter 
Total 
3 4 5 
Euthyroid 
Count 25 17 7 49 
% within MS 
parameter 
89.3% 85.0% 58.3% 81.7% 
Subclinical 
Hypothyroid 
Count 2 3 4 9 
% within MS 
parameter 
7.1% 15.0% 33.3% 15.0% 
Hypothyroid 
Count 1 0 1 2 
% within MS 
parameter 
3.6% 0.0% 8.3% 3.3% 
Total Count 28 20 12 60 
  
% within MS 
parameter 
100.0% 100.0% 100.0% 100.0% 
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Table 20: Chi-square test- thyroid status vs MS parameter 
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 6.439
a
 4 .169 
Likelihood Ratio 6.500 4 .165 
Linear-by-Linear 
Association 
3.479 1 .062 
N of Valid Cases 60     
a. 6 cells (66.7%) have expected count less than 5. The minimum expected count 
is .40. 
 
 Association between thyroid status and number of criteria positive for 
metabolic syndrome is not significant in our study 
 Now finally correlation of the individual parameters of metabolic 
syndrome in thyroid dysfunction and euthyroid in metabolic syndrome is 
studied. 
Table 21: Frequency table- thyroid dysfunction and euthyroid in 
metabolic syndrome in study subjects 
 
Frequency Percent Cumulative Percent 
Euthyroid 49 81.7 81.7 
Thyroid Dysfunction 11 18.3 100 
Total 60 100 
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Table 22: Distribution of MS parameters in Euthyroid and Thyroid 
dysfunction 
 
Thyroid status N Mean Std. Deviation 
Std. Error 
Mean 
WC 
Euthyroid 49 98.2 6.7 0.961 
Thyroid 
Dysfunction 
11 97.6 8.7 2.609 
SBP 
Euthyroid 49 140.7 15.7 2.246 
Thyroid 
Dysfunction 
11 137.6 16 4.83 
DBP 
Euthyroid 49 87.2 10.5 1.5 
Thyroid 
Dysfunction 
11 87.5 9.1 2.751 
FBS 
Euthyroid 49 138 25.4 3.622 
Thyroid 
Dysfunction 
11 126.1 10.3 3.111 
TC 
Euthyroid 49 193.3 34.5 4.934 
Thyroid 
Dysfunction 
11 197.4 26.8 8.086 
HDL 
Euthyroid 49 43.9 6.3 0.902 
Thyroid 
Dysfunction 
11 47.3 6 1.799 
TG 
Euthyroid 49 171.8 54.7 7.808 
Thyroid 
Dysfunction 
11 161.5 42.8 12.893 
 
  
55 
 
Table 23: Independent sample test 
  
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
WC 
Equal 
variances 
assumed 
0.562 0.456 0.231 58 0.818 0.547 2.367 -4.191 5.286 
Equal 
variances 
not 
assumed 
    0.197 12.848 0.847 0.547 2.78 -5.466 6.56 
SBP 
Equal 
variances 
assumed 
0.007 0.932 0.573 58 0.569 3.017 5.263 -7.519 13.552 
Equal 
variances 
not 
assumed 
    0.566 14.65 0.58 3.017 5.327 -8.361 14.395 
DBP 
Equal 
variances 
assumed 
0.23 0.633 -0.079 58 0.937 -0.271 3.429 -7.136 6.594 
Equal 
variances 
not 
assumed 
    -0.086 16.528 0.932 -0.271 3.134 -6.897 6.356 
FBS 
Equal 
variances 
assumed 
11.391 0.001 1.527 58 0.132 11.95 7.828 -3.72 27.62 
Equal 
variances 
not 
assumed 
    2.502 40.124 0.017 11.95 4.775 2.3 21.6 
HDL 
Equal 
variances 
assumed 
0.006 0.938 -1.606 58 0.114 -3.354 2.088 -7.534 0.825 
Equal 
variances 
not 
assumed 
    -1.666 15.46 0.116 -3.354 2.013 -7.634 0.925 
TG 
Equal 
variances 
assumed 
0.493 0.486 0.58 58 0.564 10.21 17.615 -25.05 45.469 
 not 
assumed 
    0.677 18.171 0.507 10.21 15.073 -21.436 41.855 
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Due to small number of study subjects correlation of metabolic 
syndrome parameters between euthyroid and thyroid dysfunction is not 
significant. 
 Lastly correlation between TSH and FT4 is analysed against metabolic 
syndrome parameters in euthyroid and thyroid dysfunction is analysed. 
Correlation is not significant in our study. 
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Table 24: correlation between TSH and FT4 and MS parameters in Euthyroid 
 
  
  FT4 TSH 
Spearman's rho 
WC 
Correlation Coefficient .139 .049 
Sig. (2-tailed) .341 .740 
N 49 49 
SBP 
Correlation Coefficient .015 .106 
Sig. (2-tailed) .921 .467 
N 49 49 
DBP 
Correlation Coefficient .067 .028 
Sig. (2-tailed) .650 .848 
N 49 49 
FBS 
Correlation Coefficient -.080 -.082 
Sig. (2-tailed) .584 .574 
N 49 49 
TC 
Correlation Coefficient -.066 .103 
Sig. (2-tailed) .654 .481 
N 49 49 
HDL 
Correlation Coefficient -.007 -.013 
Sig. (2-tailed) .960 .928 
N 49 49 
TG 
Correlation Coefficient .146 .003 
Sig. (2-tailed) .317 .985 
N 49 49 
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Table 25: correlation between TSH and FT4 and MS parameters in 
Thyroid dysfunction. 
  FT4 TSH 
Spearman's rho 
WC 
Correlation Coefficient .150 -.044 
Sig. (2-tailed) .659 .897 
N 11 11 
SBP 
Correlation Coefficient .400 -.331 
Sig. (2-tailed) .223 .320 
N 11 11 
DBP 
Correlation Coefficient .253 -.080 
Sig. (2-tailed) .452 .814 
N 11 11 
FBS 
Correlation Coefficient -.200 -.014 
Sig. (2-tailed) .555 .967 
N 11 11 
TC 
Correlation Coefficient -.301 -.096 
Sig. (2-tailed) .369 .779 
N 11 11 
HDL 
Correlation Coefficient .202 .125 
Sig. (2-tailed) .551 .714 
N 11 11 
TG 
Correlation Coefficient .400 -.140 
Sig. (2-tailed) .223 .682 
N 11 11 
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TABLE 26: DISTRIBUTION OF INDICES 
 
 
  EUTHYROID THYROID DYSFUNCTION 
  MEAN SD MEAN SD 
AGE 46.35 8.82 43.45 7.49 
HEIGHT 158.49 9.02 154.18 8.05 
WEIGHT 85.67 7.78 83.09 9.62 
BMI 27.01 1.59 26.94 2.68 
WC 98.18 6.73 97.64 8.65 
SBP 140.65 15.72 137.64 16.02 
DBP 87.18 10.5 87.45 9.13 
FBS 138.04 25.36 126.09 10.32 
TC 193.27 34.54 197.36 26.82 
HDL 43.55 6.24 47.27 5.97 
TGL 171.76 54.65 161.55 42.76 
FT4 1.13 0.24 0.82 0.24 
TSH 1.75 0.79 21.6 44.25 
 
 
 
(P valve > 0.05 not significant at 5% level) 
 
 
 
As there were small no of patients with very high variants, statistically 
Significant results were not found in our study. 
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Figure 3: Sex distribution of study subjects 
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Figure 4: MS parameter distribution 
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Figure 5: Age distribution of study subjects 
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Figure 6: Frequency of MS parameters in study subjects 
 
 
 
Table 27: Frequency table – MS parameters in study subjects. 
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Figure 7: Thyroid status of study subjects 
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Figure 8: MS parameter – Sex Distribution 
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Figure 9: Thyroid status – Age Distribution 
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Figure 10: Thyroid status vs. MS parameter 
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Figure 11: Thyroid status sex distribution 
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Figure 12: Mean MS parameter in Euthyroid and Thyroid Dysfunction 
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DISCUSSION 
―The metabolic syndrome is a cluster of metabolic abnormalities wherein 
people are obese and have hypertension, high triglyceride level, low high 
density lipoprotein cholesterol and abnormal fasting glucose levels. (4) People 
with metabolic syndrome are at high risk for developing cardiovascular disease 
and type-2 diabetes.‖ Hypothyroidism is associated with lipid abnormalities 
like high triglycerides and low high density lipoproteins, weight gain, glucose 
intolerance and hypertension. (32) Thus hypothyroidism mimics the parameters 
of metabolic syndrome. 
In this study, thyroid dysfunction prevalence is 18.33% among metabolic 
syndrome patients. Subclinical Hypothyroidism is 15% prevalent in metabolic 
syndrome patients and Overt Hypothyroidism is 3.3% prevalent. There is no 
incidence of either overt or subclinical Hyperthyroidism in our study 
population. The prevalence of thyroid dysfunction and hypothyroidism in 
metabolic syndrome patients are higher than the prevalence in normal 
population, which is 5.9% for thyroid dysfunction and 4.6% for 
hypothyroidism (0.3% overt and 4.3% sub clinical hypothyroidism)(34). This 
study is consistent with study done by Uzunulu et al, as 16.4% of metabolic 
syndrome patients had hypothyroidism in (35, 44, 46) Japan. (10) In this study 
prevalence of subclinical hyperthyroidism is 1.7% and there is no overt or 
clinical hyperthyroidism. 
In this study one sixth of metabolic syndrome patients or every sixth 
72 
 
patient with metabolic syndrome has Subclinical hypothyroidism. And one in 
every 30 patients has overt hypothyroidism. In these hypothyroidism patients, 
treatment with levothyroxine replacement reverses the symptoms and signs of 
hypothyroidism, thereby those factors which mimic metabolic syndrome. 
It is well known and proven that, by treating with levothyroxine 
replacement in all overt or clinical hypothyroid patients, we can reduce all the 
metabolic parameters and cardiovascular risk. (32) Controversy in treating sub-
clinical hypothyroidism patients. 
Managements of patients sub clinical hypothyroidism remain 
controversial because the body of scientific evidence available to guide clinical 
decision is limited. The risk of progression from subclinical hypothyroidism to 
overt hypothyroid is 2-5% per year. (46) A meta-analysis report shows that 
levothyroxine therapy in individuals with sub clinical hypothyroidism lowers 
mean serum total and low density cholesterol concentration significantly and 
the reduction in serum cholesterol may be larger in individuals with higher pre-
treatment cholesterol levels. (47) Another double blind placebo-controlled trial 
(Basal Thyroid Study) shows that an important risk reduction of cardiovascular 
mortality of 9 – 31% possible by improvement in low density lipoprotein 
cholesterol in sub clinical hypothyroidism patients treated with levothyroxine 
therapy. (48, 51) Surks et al., recommends treating sub clinical hypothyroidism 
associated with type 2 diabetes and hypertension in his scientific review. (46) 
As the metabolic syndrome patients have hyperlipidaemia, diabetes, 
hypertension and increased cardiovascular risk, its look logical to treat 
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metabolic syndrome patients having sub clinical hypothyroidism by 
levothyroxine replacement therapy. While there appears to be no adverse 
effects of initiating levothyroxine treatment in this setting, inadvertent 
overtreatment occurs in 14-21% of levothyroxine treated patients,(49, 50) 
carrying potential risks of osteoporosis and atrial fibrillation when serum TSH 
falls below 0.1 mU/L.(52) These patient need frequent thyroid function tests to 
avoid this complication. 
This study shows that the prevalence of thyroid dysfunction in metabolic 
syndrome patients is higher than in normal subjects. One sixth of metabolic 
syndrome patients or every sixth metabolic syndrome had hypothyroidism 
either overt or subclinical. This finding indicates a need for investigating the 
presence of Thyroid dysfunction during managing metabolic syndrome 
patients. As shown in previous evidences, managing these hypothyroid in 
metabolic syndrome patients are rewarding by improvement in the metabolic 
parameters and reducing cardiovascular risk. 
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CONCLUSIONS 
1. Thyroid dysfunction occurs in metabolic syndrome patients. 
2. Thyroid dysfunction occurs in 18.33% of metabolic syndrome patients. 
3. Prevalence of Subclinical hypothyroidism is 15.0% in metabolic 
syndrome patients which is higher than that of general population. 
4. Prevalence of Overt Hypothyroidism is 3.33% in metabolic syndrome 
patients which is higher than that of general population. 
5. One sixth of metabolic syndrome patients or every sixth metabolic 
syndrome had Subclinical Hypothyroidism. 
6. One in every thirty metabolic syndrome patients had Subclinical 
Hypothyroidism. 
7. Prevalence of thyroid dysfunction is much more common in Females 
with thyroid dysfunction than male. 
8. Exclude the presence of Thyroid dysfunction while managing metabolic 
syndrome patients. 
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SUMMARY 
Patients with metabolic syndrome have many symptoms and signs 
suggestive of thyroid dysfunction. It is very difficult to exclude the diagnosis of 
hypothyroidism on clinical grounds. So a study was conducted in metabolic 
syndrome patients to study the prevalence and types of thyroid dysfunction. 
Based on IDF (2005) criteria for Metabolic Syndrome, Sixty newly 
detected metabolic syndrome patients attending the outpatient department in 
Government Kilpauk Medical College and Hospital, Chennai were studied, 
after taking consent. A detailed history and clinical examination were done. 
Investigations including metabolic syndrome criteria parameters and serum free 
T4, TSH were done. 
According to thyroid function test results, 49 patients found to have 
euthyroid and two patients were hypothyroid. Nine patients had sub clinical 
hypothyroidism. No one in our study had either sub clinical or overt 
hyperthyroidism. 
The thyroid dysfunction is 18.33% prevalent in metabolic syndrome 
patients. Among the thyroid dysfunction, sub clinical hypothyroidism is highly 
prevalent – 15.0%. The overt hypothyroidism is 3.3% prevalent in metabolic 
syndrome patients . 
Thyroid dysfunction is much more prevalent in women with metabolic 
syndrome than men. Nine (40%) out of 35 women had thyroid dysfunction(1 
hypothyroid and 8 subclinical hypothyroid). Two (8%) out of 25 men had 
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thyroid dysfunction (one hypothyroid and one subclinical hypothyroid). 
In this study clearly shows that the prevalence of thyroid dysfunction in 
metabolic syndrome patients is higher than normal subjects. One sixth of 
metabolic syndrome patients or every sixth metabolic syndrome had 
Subclinical Hypothyroidism. One in every thirty metabolic syndrome patients 
had Subclinical Hypothyroidism This finding indicates a need for investigating 
the presence of Thyroid dysfunction during managing metabolic syndrome 
patients. 
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